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SUMMARY 
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1.  The ability of aminoguanidine, an inhibitor of collagen cross-linking, to prevent changes 
in cardiac and vascular structure and function has been determined in the DOCA-salt 
hypertensive rat as a model of the cardiovascular remodelling observed in chronic human 
hypertension.  
2. Uninephrectomised rats (UNX) administered DOCA (25mg every 4th day sc) and 1% 
NaCl in drinking water for 28 days developed cardiovascular remodelling shown as systolic 
hypertension, left ventricular hypertrophy, increased thoracic aortic and left ventricular wall 
thickness, increased left ventricular inflammatory cell infiltration together with increased 
interstitial collagen and increased passive diastolic stiffness, impaired contractility, 
prolongation of the action potential duration and vascular dysfunction.  
3. Treatment with aminoguanidine (0.05 – 0.1% in drinking water; average 182±17 mg kg-1 
day-1 in DOCA-salt rats) decreased blood pressure (DOCA-salt 176±4; + aminoguanidine 
144±5*mmHg; *P<0.05 vs DOCA-salt), decreased left ventricular wet weights (DOCA-salt 
3.17±0.07; + aminoguanidine 2.66±0.08*mg g-1 body wt), reduced diastolic stiffness constant 
(DOCA-salt 30.1±1.2; + aminoguanidine 24.3±1.2* (dimensionless)), improved cardiac 
contractility (DOCA-salt 1610±130; + aminoguanidine 2370±100*mmHg s-1) and vascular 
reactivity (3.4-fold* increase in maximal contractile response to noradrenaline, 3.2-fold* 
increase in maximal relaxation response to acetylcholine, 2-fold* increase in maximal 
relaxation response to sodium nitroprusside) and prolonged the action potential duration at 
50% repolarization without altering collagen content or inflammatory cell infiltration. 
4. Thus, cardiovascular function in DOCA-salt hypertensive rats can be improved by 
aminoguanidine independent of changes in collagen content. This suggests that collagen 
cross-linking is an important cause of cardiovascular dysfunction during cardiovascular 
remodelling in hypertension.  
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INTRODUCTION 
 
Cardiovascular remodelling in chronic hypertension involves ventricular hypertrophy, 
interstitial and perivascular fibrosis, electrical remodelling in the heart and endothelial 
dysfunction. The importance of the increased collagen deposition in cardiovascular 
dysfunction has long been recognised (Weber et al., 1993) with recent studies investigating 
the role of relevant mediators such as angiotensin II (Sun et al., 2004). Collagen cross-linking 
may be a more important determinant of the increased ventricular stiffness in hypertensive 
rats than collagen content (Norton et al., 1997); collagen cross-linking was increased in the 
DOCA-salt hypertensive rat (Ooshima & Midorikawa, 1977). An increased collagen cross-
linking has been proposed as the major cause of the increased arterial wall stiffness and 
decreased myocardial compliance during ageing (Lakatta, 1993; Li et al., 1996; Cantini et al., 
2001). The formation of cross-links on long-lived matrix components follows non-enzymic 
reactions between glucose and proteins to form advanced glycation end-products (AGEs) 
(Brownlee, 1995). These products are markedly increased in ageing and diabetic rats 
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(Brownlee, 1995). Increased AGE formation has also been shown in the aorta of stroke-prone 
Spontaneously Hypertensive Rats (SHRs) (Mizutani et al., 2002). Further, methylglyoxal (the 
highly reactive dicarbonyl precursor of AGEs), AGEs, oxidised glutathione and oxidative 
stress were significantly higher in vascular smooth muscle cells from 12 week old SHR 
compared with age-matched normotensive Wistar-Kyoto rats (Wu & Juurlink, 2002). In 5 
week old stroke-prone SHR, OPB-9195, an inhibitor of AGE formation, lowered systolic 
blood pressure and glycated albumin concentrations (Mizutani et al., 2002).  
 
The nucleophilic hydrazine, aminoguanidine, is an effective inhibitor of AGE formation thus 
slowing or preventing age-related aortic stiffening and cardiac hypertrophy in rats (Li et al., 
1996; Corman et al., 1998). Further, aminoguanidine is a selective inhibitor of inducible NO 
synthase (Nilsson, 1999) and may quench hydroxyl radicals and inhibit free radical 
formation, lipid peroxidation and oxidant induced apoptosis (Giardino et al., 1998). In rats, 
aminoguanidine ameliorated the neuropathic, ocular and cardiac complications of diabetes 
(Miyauchi et al., 1996; Norton et al., 1996; Swamy-Mruthinti et al., 1996), atherogenesis 
(Panagiotopoulos et al., 1998) and renal dysfunction in ageing rats (Reckelhoff et al., 1999). 
Aminoguanidine (pimegedine) has also been tested for the treatment of diabetic nephropathy 
in humans (Abdel-Rahman & Bolton, 2002).  
 
The aim of the present study was to determine whether administration of aminoguanidine 
attenuates the cardiac and vascular dysfunction in the DOCA-salt hypertensive rat, 
independent of changes in collagen content. This study has used a prevention protocol with 
oral administration of aminoguanidine following initiation of cardiovascular remodelling in 
DOCA-salt hypertensive rats. We have used echocardiography to define cardiac structure in 
vivo and the isolated Langendorff heart to define function ex vivo. Histological methods were 
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used to define infiltration of inflammatory cells and collagen deposition. Isolated thoracic 
aortic rings were used to examine endothelial dysfunction. Microelectrode studies on isolated 
left ventricular papillary muscles were used to determine changes in cardiac action potentials. 
 
MATERIALS AND METHODS 
 
DOCA-salt hypertensive rats 
Male Wistar rats aged approximately 8 weeks old were obtained from the Central Animal 
Breeding House of The University of Queensland. All experimental protocols were approved 
by the Animal Experimentation Ethics Committee of The University of Queensland, under 
the guidelines of the National Health and Medical Research Council of Australia which 
conform to the NIH Guidelines. Uninephrectomy was performed on all rats. Rats were 
anaesthetized with intraperitoneal injections of Zoletil® (tiletamine 25mg kg-1 and zolazepam 
25mg kg-1) and xylazine (10mg kg-1), a lateral abdominal incision was used to access the left 
kidney, the left renal vessels and ureter were ligated and the kidney removed. The incision 
site was surgically sutured.  Uninephrectomized rats were given either no further treatment 
(UNX rats) or 1% NaCl in the drinking water with subcutaneous injections of 
deoxycorticosterone acetate (DOCA; 25mg in 0.4ml of N,N-dimethyl formamide (DMF)) 
every fourth day (DOCA-salt rats). Rats were subsequently assigned into one of four groups: 
(i) uninephrectomized controls (UNX)(n=21); (ii) uninephrectomized controls receiving 
0.1% aminoguanidine in drinking water for 4 weeks (UNX+AG)(n=24); (iii) DOCA-salt 
hypertensive rats (DOCA)(n=29); and (iv) DOCA-salt hypertensive rats receiving 0.1% 
aminoguanidine in drinking water for 1 week, then 0.05% aminoguanidine in drinking water 
for 3 weeks (DOCA+AG)(n=31). All experiments were performed 4 weeks after 
uninephrectomy. 
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Assessment of physiological parameters 
All rats for this study were housed separately. Food and water intake and body weights were 
measured daily for all rats. Daily aminoguanidine consumption was calculated from the daily 
water intake. Systolic blood pressure was measured in selected rats lightly sedated with 
intraperitoneal Zoletil® (tiletamine 15mg kg-1 with zolazepam 15mg kg-1). A tail pulse 
transducer (MLT1010) and an inflatable tail cuff were used, connected via a Capto SP844 
physiological pressure transducer (MLT844/D) to a PowerLab data acquisition unit 
(ADInstruments, Sydney, Australia). 
 
Echocardiographic Studies 
Rats were anaesthetized with intraperitoneal injections of Zoletil® (tiletamine 25mg kg-1 and 
zolazepam 25mg kg-1) and xylazine (10mg kg-1) to produce anaesthesia with minimal 
cardiovascular depression. Serial, non-invasive, in vivo echocardiographic images were 
obtained using the Hewlett Packard Sonos 5500 echocardiography machine (12 MHz 
neonatal transducer) with an image depth of 3 cm and using 2 focal zones (Brown et al., 
2002). Left ventricular M-mode measurements at the level of the papillary muscles were used 
to obtain wall thicknesses. Suprasternal long axis views were used to obtain the internal 
diameters of the ascending aortic arch (Brown et al., 2002). 
 
Isolated Heart Preparations 
The diastolic stiffness constant was determined using a non-recirculating isolated 
Langendorff heart preparation (Brown et al., 1999). Briefly, rats were anaesthetized with 
sodium pentobarbitone (60mg intraperitoneal) and heparin (200 IU.kg-1) was administered via 
the femoral vein. After two minutes, the heart was rapidly excised and stunned in ice-cold 
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crystalloid perfusate (modified Krebs-Henseleit bicarbonate buffer (KHB) containing [in mM]: 
NaCl 119.1; KCl 4.75; MgSO4 1.19; KH2PO4 1.19; NaHCO3 25.0; glucose 11.0 and CaCl2 
2.16). The aorta was isolated and cannulated via the dorsal root. Retrograde perfusion was 
initiated at 100cm of constant pressure with KHB bubbled with carbogen (95% O2/5% CO2), 
giving a pH of 7.4 and the temperature maintained at 35±0.5ºC. A water-filled latex balloon 
catheter was inserted in the left ventricle via the mitral orifice for measurement of left 
ventricular developed pressures. The catheter was connected via a three-way tap to a micrometer 
syringe and to a disposable pressure transducer (MLT844, ADInstruments) via a disposable clip-
on dome (MLA844, ADInstruments) all connected to a MacLab system. The hearts were 
electrically paced at 250 beats min-1 by touching two electrodes to the surface of the right 
atrium. End-diastolic pressures were measured from 0 to 30mmHg. Myocardial diastolic 
stiffness was calculated as the diastolic stiffness constant (κ, dimensionless), that is the slope of 
the linear relation between stress (σ, dyne cm-2) and tangent elastic modulus (E, dyne cm-2) 
(Brown et al., 1999). To assess contractile function, maximum +dP/dT (rate of contraction) and 
–dP/dT (rate of relaxation) were calculated at a diastolic pressure of 10mmHg.   
 
Histological studies of left ventricular collagen distribution, inflammatory cell infiltration 
and thoracic aortic wall thickness 
Left ventricles (at mid-papillary level) and thoracic aortas were cut transversely, treated with 
Telly’s fixative and Bouin’s solution and stained with picrosirius red as previously described 
(Allan et al., 2005; Fenning et al., 2005). Thoracic aortic wall thicknesses were also 
measured using NIH-image software (National Institute of Health, USA). For left ventricular 
inflammatory cell infiltration measurements, sections of 5 µm thickness were stained with 
hematoxylin and eosin. Inflammatory cells were identified by cell morphology and analysed 
via a blinded experimenter protocol using a Meopta binocular light microscope. Sections 
 7
   
were examined for pathology as shown by the presence of inflammatory cells (for example, 
polymorphonuclear neutrophils (PMNs)), and graded on a scale of 0-4. For grading, a 45X 
lens was used while a 100X lens was used to check cell/nucleus morphology. Sections were 
given a grade of 1 if no abnormalities were detected. A grade of 1 indicated the appearance of 
low numbers of PMNs in the interstitial spaces. A grade of 2 indicated the presence of PMNs 
in higher numbers and moderate infiltration to other areas of the interstitium. A grade of 3 
was given to indicate a more prominent presence of PMNs in the interstitium and significant 
infiltration to other areas of the myocardium. A maximal grade of 4 indicated severe scarring 
of the myocardium and high levels of PMNs in the interstitium especially accumulating 
within the scar tissues and throughout the myocardium.  
 
Microelectrode studies  
Isolated left ventricular papillary muscles were prepared for microelectrode studies as 
previously described (Fenning et al., 2005). After equilibration, action potential durations at 
20%, 50% and 90% of repolarization were recorded from the papillary muscle over a 30-
minute period, while continually being perfused with a drug-free Tyrode solution. Data were 
acquired, derived and analysed using Chart software (ADInstruments).   
 
Isolated Thoracic Aortic rings 
Thoracic aortic rings (approximately 4 mm in length) were suspended in an organ bath 
chamber with a resting tension of 10 mN and bathed in a modified Tyrode solution containing 
[in mM]: NaCl 136.9; KCl 5.4; MgCl2 1.05; CaCl2 1.8; NaHCO3 22.6; NaH2PO4 0.42; glucose 
5.5; ascorbic acid 0.28 and sodium ethylene diamine tetra-acetic acid (EDTA) 0.1. The Tyrode 
solution was bubbled with carbogen (95% O2/5% CO2) and the temperature maintained at 
35±0.5ºC.  Force of contraction was measured isometrically with Grass FT03C force transducers 
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connected via amplifiers to a Macintosh computer via a MacLab system (Brown et al., 1991). 
Cumulative concentration-response curves were performed for noradrenaline and either 
acetylcholine or sodium nitroprusside in the presence of a submaximal (approximately 70%) 
contraction to noradrenaline. 
 
Statistical Analysis 
All values are presented as mean ± standard error of the mean (SEM). The -log EC50 was 
determined from the concentration giving half-maximal responses in individual 
concentration-response curves.  Statistical comparisons of the group means were made by 
one-way analysis of variance (ANOVA) with a Bonferroni post-test analysis for multiple 
groups or by paired or unpaired Student’s t-test as appropriate for two group comparison.  
P<0.05 was considered statistically significant. 
 
Drugs 
Aminoguanidine hemisulfate, deoxycorticosterone acetate, heparin, noradrenaline, 
acetylcholine and sodium nitroprusside were purchased from Sigma-Aldrich Chemical 
Company, St Louis, MO, USA.  Noradrenaline, acetylcholine and sodium nitroprusside were 
dissolved in distilled water; deoxycorticosterone acetate was dissolved in dimethylformamide 
with mild heating. 
 
 
 
 
RESULTS 
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Physiological parameters 
Daily aminoguanidine doses remained relatively constant over the 4 weeks with an average 
daily dose for UNX+AG rats of 97±4 mg kg-1 day-1 (n=16-28), and an average daily dose for 
DOCA+AG rats of 182±17 mg kg-1 day-1 (n=16-28) (Figure 1). DOCA-salt rats developed 
hypertension; aminoguanidine treatment significantly lowered systolic blood pressures in 
both UNX+AG and DOCA+AG groups (Table 1). 
 
Structural parameters 
DOCA-salt rats exhibited marked cardiovascular remodelling, including left and right 
ventricular hypertrophy, increased left ventricular wall thickness, increased thoracic aortic 
wall thickness and decreased ascending aortic arch diameter but without dilatation of the left 
ventricular chamber (Table 1). Furthermore, DOCA-salt rats showed increased left 
ventricular interstitial inflammatory cell infiltration together with left ventricular interstitial 
fibrosis (Table 1). Treatment with aminoguanidine in the DOCA-salt rats attenuated the 
increase in left and right ventricular wet weights and prevented the decrease in ascending 
aortic arch diameter (Table 1). Aminoguanidine did not significantly alter inflammatory cell 
infiltration or left ventricular fibrosis (Table 1).   
 
Functional parameters 
DOCA-salt hypertensive rats exhibited significantly increased passive diastolic stiffness 
(Table 1), reduced maximal rates of contraction and relaxation together with prolongation of 
the action potential durations at 20% and 90% of repolarization (Table 1). Vascular 
dysfunction was also evident in the DOCA-salt rats as shown by reduced maximal contractile 
responses to noradrenaline and reduced maximal endothelium-dependent relaxation to 
acetylcholine and endothelium-independent relaxation to sodium nitroprusside (Figure 2). 
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Treatment with aminoguanidine in the DOCA-salt rats prevented the increased diastolic 
stiffness and improved rates of contraction and relaxation (Table 1). In addition, 
aminoguanidine increased action potential durations at 50% of repolarization but did not 
affect action potential durations at 20% and 90% of repolarization (Table 1). Finally, 
aminoguanidine treatment prevented the decreased maximal vascular contractile and relaxant 
responses in the DOCA-salt hypertensive rats (Figure 2). 
 
DISCUSSION 
 
Long-lived proteins such as collagen undergo continual non-enzymatic cross-linking with 
advanced glycation end-products (AGEs) during ageing (Lakatta, 1993; Corman et al., 1998) 
as well as in diabetes (Brownlee, 1995; Norton et al., 1996) and hypertension (Mizutani et 
al., 2002; Wu & Juurlink, 2002). Aminoguanidine inhibits the formation of collagen cross-
linking by reacting with the reactive glucose-protein Amadori product and forming an 
unreactive substituted Amadori product that cannot form AGEs (Brownlee et al., 1986; 
Edelstein & Brownlee, 1992). Increased collagen cross-linking has been shown to correlate 
with increased myocardial and vascular stiffness (Corman et al., 1998; Badenhorst et al., 
2003). Thus, inhibition of collagen cross-linking and AGE formation should decrease AGE-
induced cross-linking and decrease stiffness. Aminoguanidine has additional actions that may 
be of relevance in the prevention of cardiovascular disease. It is a selective inhibitor of the 
endotoxin-induced or cytokine-induced inducible nitric oxide synthase (iNOS) isoform 
(Griffiths et al., 1993). By inhibiting iNOS, aminoguanidine may also decrease the formation 
of peroxynitrite (Hong et al., 2000), a pro-oxidant and an effective contributor to endothelial 
dysfunction (Kojda & Harrison, 1999). Aminoguanidine may also act an as antioxidant in the 
DOCA-salt rat, a model of increased superoxide production (Somers et al., 2000; Wu et al., 
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2001), by quenching hydroxyl radicals and inhibiting free radical formation (Giardino et al., 
1998). Further, AGEs binding to their receptor RAGE triggers a cascade of events leading to 
intracellular generation of free radicals, oxidative stress and activation of the transcription 
factor NF-κB (Yan et al., 1994; Lander et al., 1997); inhibition of AGE formation may 
prevent this cascade.  
 
One possible mechanism of action of aminoguanidine in DOCA-salt rat hearts is as an iNOS 
inhibitor (Nilsson, 1999). Inflammatory cell infiltration has been demonstrated in the left 
ventricles of DOCA-salt rats (Fujisawa et al., 2001; Ammarguellat et al., 2002) and iNOS 
has been implicated in inflammation (Salvemini et al., 1995) and myocardial dysfunction 
(Salvemini et al., 1995; Oyama et al., 1998). However, it is important to note that as 
increased iNOS activity is characteristic of inflammation, a selective reduction in iNOS 
activity should also result in a reduction in inflammation. In this study, aminoguanidine did 
not reduce inflammatory cell infiltration into the myocardium, suggesting that iNOS 
inhibition by aminoguanidine is unlikely to be a major mechanism in the cardiac responses in 
the current study. The reduced response in thoracic aorta from UNX rats to acetylcholine 
could be due to inhibition of NO synthase in endothelial cells by aminoguanidine; however, 
this does not seem to apply to aorta from DOCA-salt rats where the endothelium is damaged.  
 
The dosage of aminoguanidine used for this study was based on previous studies using 0.1% 
in the drinking water (Li et al., 1996; Reckelhoff et al., 1999). Since dose depends on water 
intake, this protocol produced different doses to DOCA-salt and control (uninephrectomized) 
rats. However, a wide range of aminoguanidine doses has been reported (25mg kg-1 
(Brownlee et al., 1986), 100mg kg-1 (Kochakian et al., 1996), 250mg kg-1 (Bucala et al., 
1991) and 7.35mmol kg-1 (which as a free base equates to approximately 545mg kg-1) 
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(Norton et al., 1996)), all shown to be effective in inhibiting the formation of AGEs and 
cross-linking. Thus, it is likely that the average aminoguanidine dose administered in this 
study would be effective in inhibiting collagen cross-linking.  
 
Most experimental studies have investigated the role of increased collagen cross-linking in 
ageing and diabetes, rather than in hypertension. An increased cross-linking was shown in 
DOCA-salt hypertensive rats (Ooshima & Midorikawa, 1977) and in Spontaneously 
Hypertensive Rats (Badenhorst et al., 2003) but not in aortic-banded pressure overload 
hypertrophy (Badenhorst et al., 2003). Methylglyoxal, the precursor of AGEs, and AGE 
formation were increased in the vascular tissues of Spontaneously Hypertensive Rats 
(Mizutani et al., 2002; Wu & Juurlink, 2002); inhibition of AGE formation lowered systolic 
blood pressure and glycated albumin concentrations (Mizutani et al., 2002). As far as we are 
aware, this is the first study to show that a compound known to reduce collagen cross-linking 
can improve cardiac function in hypertensive rats.  
 
Endothelial dysfunction is characteristic of the DOCA-salt rat (Kirchner et al., 1993; Somers 
et al., 2000). Numerous studies have shown favourable effects of aminoguanidine on the 
vasculature of ageing and diabetic rats by decreasing cross-linking, reducing reactive oxygen 
species and inhibiting quenching of nitric oxide (Bucala et al., 1991; Li et al., 1996; Corman 
et al., 1998). This study shows that this improvement can also be demonstrated in the DOCA-
salt hypertensive rat. Changes in blood pressure as in the DOCA-salt hypertensive rat may 
lead to vascular remodelling to maintain the wall stress, according to the LaPlace 
relationship. An analysis of wall thicknesses at the operating pressure in treated and untreated 
rats, rather than in vitro in an isolated vessel, may allow estimation of changes in wall stress 
during treatment.  
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Action potential prolongation in hypertrophied DOCA-salt hearts is probably caused by a 
reduction in the transient outward potassium current (Ito) (Momtaz et al., 1996). However, 
aminoguanidine appeared to have minimal effects on regulating potassium currents in our 
study. We have shown prolongation of the APD50 in DOCA-salt rats treated with 
aminoguanidine. Prolongation of APD50 is believed to be primarily due to an increased L-
type Ca2+ inward current (ICa) (Hart, 1994). Aminoguanidine has been shown to reverse the 
depression of the L-type calcium current in transplanted myocytes (Ziolo et al., 2001). Thus, 
this could be one mechanism by which aminoguanidine treatment selectively prolonged 
APD50 in these rats.  
 
In summary, it is likely that inhibition of AGE-induced collagen cross-linking as well as its 
antioxidant properties contributed to the favourable effects of aminoguanidine on 
hypertension, hypertrophy, cardiac contractility and vascular reactivity without necessarily 
reducing fibrosis, inflammatory cell infiltration or iNOS activity in the DOCA-salt rats.  
Furthermore, this study clearly supports the concept that improvement in function is not 
necessarily dependent on a reduced content of collagen but rather reduced collagen cross-
linking. Indeed, if collagen cross-linking plays such an important role in hypertension, the 
use of selective AGE cross-link breakers such as ALT-711 (Vasan et al., 2003; Bakris et al., 
2004) could be of significant therapeutic importance in reversing end-organ damage in 
hypertension.  A recent study by Little and coworkers (2005) demonstrated that treatment 
with ALT-711 decreased left ventricular mass and improved left ventricular diastolic filling 
parameters and quality of life in patients with diastolic heart failure. Although experience 
with ALT-711 in clinical studies is still limited, this compound is a potential treatment for the 
symptoms of diastolic heart failure (Little et al., 2005; Redfield, 2005).   
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Table 1: Physiological parameters 
Parameter UNX 
4wk 
UNX + 
aminoguanidine 
DOCA-salt   
4wk 
DOCA-salt + 
aminoguanidine 
Systolic blood 
pressure 
(mmHg) 
128 ± 5 (12) 117 ± 3* (11) 176 ± 4* (11) 144 ± 5** (12) 
Initial body 
weight (g) 
326 ± 3 (17) 338 ± 8 (21) 341 ± 8 (17) 344 ± 6 (26) 
Final body 
weight (g) 
431 ± 8 (17) 440 ± 10 (19) 354 ± 10* (16) 369 ± 5 (21) 
LV+septum 
weight  
(mg g-1 bodywt) 
1.97 ± 0.04 
(15) 
2.08 ± 0.04 (12) 3.17 ± 0.07* (14) 2.66 ± 0.08** 
(10) 
RV weight  
(mg g-1 bodywt) 
0.57 ± 0.02 
(15) 
0.53 ± 0.02 (12) 0.65 ± 0.02* (14) 0.56 ± 0.03** 
(10) 
Thoracic aortic 
wall thickness 
(µm) 
123 ± 4 (6) 121 ± 5 (8) 157 ± 6* (7) 145 ± 5* (8) 
LV interstitial 
inflammation 
(grade) 
0.8 ± 0.4 (5) 0.8 ± 0.4 (5) 2.8 ± 0.4* (5) 2.8 ± 0.6* (5) 
LV interstitial 
area of collagen 
(%) 
2.71 ± 0.21 
(7) 
4.06 ± 0.77 (8) 14.43 ± 1.75* (8) 10.96 ± 1.42* (8) 
Diastolic 
stiffness (κ) 
22.2 ± 1.2 
(12) 
19.4 ± 0.9 (12) 30.1 ± 1.2* (12) 24.3 ± 1.2** (10) 
 +dP/dTmax 
(mmHg sec-1) 
2080 ± 70 (8) 2340 ± 130* (12) 1610 ± 130* (13) 2370 ± 100** 
(10) 
 –dP/dTmax 
(mmHg sec-1) 
-1590 ± 50 
(9) 
-1550 ± 60 (12) -1320 ± 70* (12) -1480 ± 40** (10) 
LVPWd (mm) 1.5 ± 0.1 (15) 1.7 ± 0.1* (11) 2.0 ± 0.1* (14) 2.0 ± 0.1* (14) 
LVIDd (mm) 6.8 ± 0.2 (17) 7.1 ± 0.3 (13) 6.6 ± 0.2 (15) 6.6 ± 0.2 (15) 
Ejection fraction 
(%) 
91.0 ± 1.5 
(16) 
92.6 ± 1.4 (13) 93.8 ± 0.9 (15) 93.3 ± 1.4 (15) 
Ascending aortic 
arch diameter 
(mm) 
3.3 ± 0.1 (7) 3.6 ± 0.1* (12) 2.9 ± 0.1* (5) 3.3 ± 0.1** (14) 
APD20 (msec) 6.8 ± 1.1 (8) 6.9 ± 1.1 (4) 10.1 ± 1.5* (7) 10.7 ± 1.0* (4) 
APD50 (msec) 16.4 ± 2.0 (8) 22.8 ± 4.9 (4) 19.8 ± 2.7 (7) 42.4 ± 6.2** (4) 
APD90 (msec) 34.4 ± 3.5 (8) 38.4 ± 7.7 (4) 59.1 ± 10.3* (7) 76.8 ± 11.2* (4) 
All values shown represent the mean ± SEM (n value); LV=left ventricular, RV=right 
ventricular, LVPWd = left ventricular posterior wall thickness in diastole; LVIDd = left 
ventricular internal diameter in diastole; APD=action potential duration at 20, 50 or 90% of 
repolarization. Significance: *p < 0.05 vs UNX rats; **p < 0.05 vs DOCA-salt rats. 
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Legends to figures: 
 
Figure 1. Daily aminoguanidine dose (mg kg-1) of UNX rats treated with aminoguanidine and 
DOCA-salt rats treated with aminoguanidine. Values are mean±SEM; n=16-28 for all groups. 
 
Figure 2. Concentration-response curves to noradrenaline (A) for UNX rats (-log EC50 
7.4±0.1, n=9), UNX rats treated with aminoguanidine (-log EC50 7.7±0.1, n=7), DOCA-salt 
rats (-log EC50 7.8±0.1, n=9) and DOCA-salt rats treated with aminoguanidine (-log EC50 
8.0±0.1 n=7).  Concentration-response curves to acetylcholine (B) for UNX rats (-log EC50 
7.0±0.1, n=9), UNX rats treated with aminoguanidine (-log EC50 7.1±0.2, n=7), DOCA-salt 
rats (-log EC50 7.0±0.1, n=9) and DOCA-salt rats treated with aminoguanidine (-log EC50 
7.6±0.2 n=7).  Concentration-response curves to sodium nitroprusside (C) for UNX rats (-log 
EC50 7.8±0.1, n=9), UNX rats treated with aminoguanidine (-log EC50 7.7±0.1, n=7), 
DOCA-salt rats (-log EC50 7.4±0.1, n=9) and DOCA-salt rats treated with aminoguanidine (-
log EC50 8.0±0.2 n=7).  Values are mean±SEM; Significance: *p < 0.05 vs UNX rats; **p < 
0.05 vs DOCA-salt rats. 
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